06 November 2023
06 November 2023
The expanded agreement grants Pierre Fabre marketing rights to Ebvallo in the US, Canada, and other remaining territories.
Small molecule sales account for approximately 60% of global market revenue, as per GlobalData.
Kronos Bio joins other pharma companies in workforce reductions, cutting 19% of its employees to support clinical development.
Two more medtech darlings have closed their doors this week, signalling an end to the funding rush of Covid.
BioCina will produce batches for the vaccine programme against Streptococcus pneumoniae at its facility in Adelaide, Australia.
The deal was terminated after the criteria for closure of the initial merger and further amendments were not met by 3 November 2023.
Lupin will own semi-exclusive rights for co-marketing the drug in the country under the brand name LINVAS.
GC1109 has a protective antigen as its active pharmaceutical ingredient, created using recombinant DNA technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
